<DOC>
	<DOCNO>NCT00968214</DOCNO>
	<brief_summary>RATIONALE : Studying sample tumor tissue blood patient cancer laboratory may help doctor learn change occur DNA identify biomarkers related cancer . It may also help doctor predict patient respond treatment . PURPOSE : This research study look tumor blood sample postmenopausal woman primary breast cancer enrol clinical trial CAN-NCIC-MA27 .</brief_summary>
	<brief_title>Study Tumor Blood Samples From Postmenopausal Women With Primary Breast Cancer Enrolled Clinical Trial CAN-NCIC-MA27</brief_title>
	<detailed_description>OBJECTIVES : Primary - To identify genetic variation , measure single nucleotide polymorphism , associate musculoskeletal adverse event specimens postmenopausal woman hormone receptor-positive primary breast cancer receive adjuvant aromatase inhibitor enrol clinical trial CAN-NCIC-MA27 . OUTLINE : This multicenter study . DNA tumor tissue blood specimens previously collect patient analyzed single nucleotide polymorphism .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm invasive breast cancer Complete resection primary tumor Stage IIII ( T13 , N03 , M0 ) disease Enrolled clinical trial CANNCICMA27 . No locally recurrent metastatic breast cancer Hormone receptor status : Estrogen receptor progesterone receptorpositive disease PATIENT CHARACTERISTICS : Postmenopausal status , define one following : At least 60 year old Age 4559 year spontaneous cessation menses &gt; 12 month prior chemotherapy study randomization Age 4559 year cessation menses &lt; 12 month secondary hysterectomy AND folliclestimulating hormone ( FSH ) level postmenopausal range ( &gt; 34.4 IU/L ) Age 4559 year hormone replacement therapy ( HRT ) discontinue HRT diagnosis breast cancer AND FSH level postmenopausal range ( &gt; 34.4 IU/L ) Bilateral oophorectomy PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage IA breast cancer</keyword>
	<keyword>stage IB breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>estrogen receptor-positive breast cancer</keyword>
	<keyword>progesterone receptor-positive breast cancer</keyword>
</DOC>